All non-vascular SAEs, by particular baseline characteristics. Figure S2. All non-vascular SAEs, by system of disease and dialysis status. Figure S3. All non-vascular SAEs, by duration of follow-up. (PDF 21 kb
Table S1. Adjusted Spearmanâs correlation coefficient (r) between the variables and estimated glom...
(a) Ferritin and (b) transferrin saturation (TSAT) for patients with eGFR values at baseline and mon...
Table S2. Crude and adjusted assessment of echocardiographic parameters and estimated glomerular fil...
Kaplan-Meier survival curves for CVD mortality in three HDL-C groups of LN patients. There were no s...
Additional file 3: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Estimation of average treatment model for ESRD in diabetic patients. Table S2. Estimation of average...
Figure S1. Flowchart for patient selection. CKD, chronic kidney disease; ESRD, end-stage renal disea...
Table S1. Multivariable-adjusted hazard ratios of atherosclerotic cardiovascular composite endpoints...
Anticipated and actual target distributions of CKD etiology and renal function, C-STRIDE study (Nov ...
Comparisons of baseline characteristics between LN patients with and without follow-up data. Table S...
Figure S1. Flow Diagram. Figure S2. Assessment of exposure to statins. Table S1. Classification of s...
Additional file 4: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Additional file 6: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Additional file 7: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
The biomarker hazard ratios using Cox proportional hazards models that included GN vs non-GN CKD and...
Table S1. Adjusted Spearmanâs correlation coefficient (r) between the variables and estimated glom...
(a) Ferritin and (b) transferrin saturation (TSAT) for patients with eGFR values at baseline and mon...
Table S2. Crude and adjusted assessment of echocardiographic parameters and estimated glomerular fil...
Kaplan-Meier survival curves for CVD mortality in three HDL-C groups of LN patients. There were no s...
Additional file 3: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Estimation of average treatment model for ESRD in diabetic patients. Table S2. Estimation of average...
Figure S1. Flowchart for patient selection. CKD, chronic kidney disease; ESRD, end-stage renal disea...
Table S1. Multivariable-adjusted hazard ratios of atherosclerotic cardiovascular composite endpoints...
Anticipated and actual target distributions of CKD etiology and renal function, C-STRIDE study (Nov ...
Comparisons of baseline characteristics between LN patients with and without follow-up data. Table S...
Figure S1. Flow Diagram. Figure S2. Assessment of exposure to statins. Table S1. Classification of s...
Additional file 4: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Additional file 6: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
Additional file 7: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...
The biomarker hazard ratios using Cox proportional hazards models that included GN vs non-GN CKD and...
Table S1. Adjusted Spearmanâs correlation coefficient (r) between the variables and estimated glom...
(a) Ferritin and (b) transferrin saturation (TSAT) for patients with eGFR values at baseline and mon...
Table S2. Crude and adjusted assessment of echocardiographic parameters and estimated glomerular fil...